As a potential treatment of COVID-19: Montelukast
| dc.contributor.author | Fidan, Cihan | |
| dc.contributor.author | Aydogdu, Ayse | |
| dc.contributor.orcID | 0000-0002-9093-1524 | en_US |
| dc.contributor.pubmedID | 32416408 | en_US |
| dc.contributor.researcherID | F-5830-2019 | en_US |
| dc.date.accessioned | 2021-05-16T16:37:29Z | |
| dc.date.available | 2021-05-16T16:37:29Z | |
| dc.date.issued | 2020 | |
| dc.description.abstract | It has been hypothesized that Montelukast, a cysteinyl leukotriene (cysLT) receptor antagonist, with effects of anti-inflammatory, suppress oxidative stress and reduce affect cytokine production, may limited progression of the disease on COVID-19 infection. | en_US |
| dc.identifier.issn | 0306-9877 | en_US |
| dc.identifier.scopus | 2-s2.0-85084495386 | en_US |
| dc.identifier.uri | http://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC7211747&blobtype=pdf | |
| dc.identifier.uri | http://hdl.handle.net/11727/5865 | |
| dc.identifier.volume | 142 | en_US |
| dc.identifier.wos | 000565195600019 | en_US |
| dc.language.iso | eng | en_US |
| dc.relation.isversionof | 10.1016/j.mehy.2020.109828 | en_US |
| dc.relation.journal | MEDICAL HYPOTHESES | en_US |
| dc.rights | info:eu-repo/semantics/openAccess | en_US |
| dc.title | As a potential treatment of COVID-19: Montelukast | en_US |
| dc.type | Letter | en_US |